Keros Therapeutics Stock Filter Stocks by Fundamentals
| KROS Stock | USD 56.58 0.66 1.18% |
Keros Therapeutics fundamentals help investors to digest information that contributes to Keros Therapeutics' financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros Therapeutics stock.
Keros | Shares Owned by Institutions |
Keros Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 172.6M | 828.8M | 1.1B | 946.3M | 854.1M | 545.9M |
Keros Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Keros Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Keros Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Keros Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Keros Therapeutics' value.| Shares | Holocene Advisors, Lp | 2024-09-30 | 843.1 K | Woodline Partners Lp | 2024-06-30 | 775.8 K | Geode Capital Management, Llc | 2024-09-30 | 725.6 K | Braidwell Lp | 2024-09-30 | 707.2 K | Citadel Advisors Llc | 2024-09-30 | 704.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 671.3 K | Redmile Group, Llc | 2024-09-30 | 552.5 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 525 K | Goldman Sachs Group Inc | 2024-06-30 | 521.4 K | Fmr Inc | 2024-09-30 | 4.9 M | Blackrock Inc | 2024-06-30 | 2.5 M |
Keros Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (151.18) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 40.51 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 94.60 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Book | 4.25 X | ||||
| Price To Sales | 3,480 X | ||||
| Revenue | 151 K | ||||
| Gross Profit | (87.27 M) | ||||
| EBITDA | (152.18 M) | ||||
| Net Income | (152.99 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 14.44 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 13.57 X | ||||
| Cash Flow From Operations | (124.51 M) | ||||
| Short Ratio | 7.80 X | ||||
| Earnings Per Share | (5.22) X | ||||
| Target Price | 90.69 | ||||
| Number Of Employees | 160 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 2.27 B | ||||
| Total Asset | 370.02 M | ||||
| Retained Earnings | (381.43 M) | ||||
| Working Capital | 322.92 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 370.02 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.